Characteristics of patients with long-term survival of recurrent glioma after bevalmono treatment

Background
methodology
the study retrieved 1,397 patients treated with Bev in adult adults treated with Bev at the University of California, Los Angeles (UCLA) and Kaiser Medical Facility (KPLA) from 2004 to 2017Long-term survivors (Bev-LTS) treated with Bev afterglioma relapse are defined as patients with a total survival period of 3 years from Bev treatmentpre-PFSdefined as the time between the onwards and the first recurrence of glioma diagnosisprogression-free survival is defined as the time between the time began and the tumor relapsed when Bev treated recurrent gliomasuncertain "pseudo" progression is defined as a patient who has relapsed glioma for the first time within 3 months of radiation therapyresearchers divided bev-LTS glioma patients into five subgroups of survival patterns:A (early Bev therapy and long-term PFS), Group B (late Bev therapy and long-term PFS), Group C (late Bev treatment and short-term PFS), Group D (uncertain "pseudo" progressives) and Group E (early Bev treatment and short-term PFS)the first relapse using Bev therapy is called early Bev therapy, while the relapse is applied to Bev therapy called late Bev therapythe authors define PFS as long-term PFS and PFS 4.1 months as short-term PFSfindingsfindings found that 50 of the 1,397 patients with recurrent glioma were identified as Bev-LTS patients28 cases (2.9 per cent) of WHO IV gliomas, including 27 cases of GBM and 1 gliosarsar (
glio); WHO CLASS III GLIOMA 14 cases (6.3%), including 6 cases of intersasexual asexual atomoma (AA), 3 cases of interdesist hybrid glioma (AMG) and 5 cases of interdestuous glioma (AO);3 of 27 GBM patients, 1 in 6 AA patients and 2 LA cases defined as uncertain (false) progressionthe researchers assessed data such as tumor resection, KPS, tumor recurrence rate and tumor size after Bev treatment, and biomarkers of IDH1, IDH2, and MGMT-methylation status at the initial diagnosisthe results of the survival pattern analysis of Bev-LTS patients after the exclusion of uncertain (false) progression were as follows, (1) the prior stage of non-progression after the first surgery:WHO CLASS IV and Class III group AA/AMG patients with median pre-PFS were 8.9 months and 18 months, respectivelythe highest median pre-PFS in the AO and LO groups, at 29.8 months and 24.5 months, respectively(2) No progress iver after using Bev:The PFS in the LO group was 38.8 months, the highest of all groupswho is second in the AO class of IV and WHO III, at 28.9 months and 22.2 months, respectively, with the lowest PFS in the AA/AMG group at 8 months(3) Total Lifetime (OS) after Using Bev:The median OS in the WHO IV, WHO III, aO and AA/AMG groups were all around 51 monthsThe highest number of bit OS in theLO group was 109.8 months(4) The longest survivalwas in 1 WHO Class III AO patient, OS for 12 years 1 WHO Class III AA patient with OS for 10 years 2 GBM patients with OS for 10 years, 8 cases of OS for 5 years, 1 case of AMG patients and 1 case of AO patients OS for 5 years in the WHO CLASS II LA/LGMO group, 1 patient showed no false progression, with pre-PFS at 6.4 months, PFS at 24.5 months and OS at 43.3 months among those who had a false progression, there was 1 GBM and 1 WHO CLASS II LA patient with OS for 5 years (Table 1) Table 1 Summary of survival patterns in patients who have survived long-term survival in the treatment of recurrent glioma Bev analyzed the basic characteristics of Bev treatment timing (early/late) and PFS (long/short) subgroup (A-D group) patients in Bev-LTS patients, found that 23 patients in Group A (early Bev treatment and long-term PFS) included WHO IV-class GBM 16 cases, WHO III-class AA patients 4, AO 1, WHO-CLASS LO 1, LGMO 1 patients; of these, the median PFS in 16 WHO CLASS IV patients was 29.8 months and the OS was 55.3 months group B (advanced Bev therapy and long-term PFS) patients, including WHO IV-grade GBM 7 and GLIO 1, WHO CLASS III AO 4 and AMG 1 case, 7 PATIENTs with WHO IV-class PFS were 22.9 months and median OS was 55.5 months group C (late-stage Bev therapy and short-term PFS) patients, including WHO IV-grade GBM 1 and WHO III-class AA 1, AO 1 and AMG 1 group of patients with uncertain (false) progression, including WHO IV-grade GBM 3, WHO III-class AA 1, WHO CLASS II LA 1 The median size of the Group A and Group B WHO IV tumors was 1328mm2 and 1110mm2, respectively conclusions the study shows that some patients with recurrent gliomas who were initially diagnosed with WHO Grade II, III and IV actually achieve long-term survival after using bevalipros but there is no definitive evidence that long-term survival of patients is a direct result of the application of bevalone suggests further screening of Bev-LTS patients with molecular pathology diagnosis or clinical data from a large number of patients with recurrent gliomas to study the appropriate timing of administration.